This article is more than 5 years old. Information may no longer be current.
Alcon launches ocriplasmin in UK market
Click Here to Manage Email Alerts
Alcon has launched ocriplasmin for the treatment of vitreomacular traction in the United Kingdom, its first market in Europe, according to a news release from ThromboGenics.
Alcon, which has the rights to commercialize Jetrea (ocriplasmin, ThromboGenics) outside the United States, paid ThromboGenics €45 million when the European Commission approved ocriplasmin to treat vitreomacular traction, including when associated with a macular hole of 400 µm or less in diameter, earlier this year.
The first U.K. sale will trigger another €45 million payment from Alcon, a division of Novartis, to ThromboGenics.
The National Institute for Health and Care Excellence is performing a single technology appraisal of ocriplasmin, expected to be completed this year, to determine reimbursement when it is used by the U.K. National Health Service, the release said.
ThromboGenics holds the rights to commercialize ocriplasmin in the United States, where it gained U.S. Food and Drug Administration approval for treatment of vitreomacular traction in October 2012.